An Open-Label Re-Treatment Trial for Patients Previously Randomized Into the SL0003 and SL0004, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studies of Epratuzumab in Patients With Systemic Lupus Erythematosus.

Trial Profile

An Open-Label Re-Treatment Trial for Patients Previously Randomized Into the SL0003 and SL0004, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studies of Epratuzumab in Patients With Systemic Lupus Erythematosus.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Epratuzumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Registrational
  • Sponsors UCB
  • Most Recent Events

    • 14 Nov 2012 Health-related quality-of-life results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 13 Nov 2012 Quality-of-life results were presented at the Annual Meeting of the American College of Rheumatology (ACR) in November 2012
    • 12 Nov 2012 Long-term efficacy and safety results were presented at the 2012 American College of Rheumatology Annual Scientific Meeting, according to an Immunomedics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top